Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

731 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Warburton C, et al. Among authors: chia s. Clin Cancer Res. 2004 Apr 1;10(7):2512-24. doi: 10.1158/1078-0432.ccr-03-0244. Clin Cancer Res. 2004. PMID: 15073131
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. Gelmon KA, et al. Among authors: chia s. Ann Oncol. 2004 Jul;15(7):1115-22. doi: 10.1093/annonc/mdh278. Ann Oncol. 2004. PMID: 15205207 Clinical Trial.
The 2000 EBCTCG overview: a widening gap.
Chia S, Bryce C, Gelmon K. Chia S, et al. Lancet. 2005 May 14-20;365(9472):1665-6. doi: 10.1016/S0140-6736(05)66524-5. Lancet. 2005. PMID: 15894082 No abstract available.
731 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page